For immediate release
21 October 2014
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 September 2014
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2014 was 14.42 pence per share, including un-invested cash of £490,797. The accrual of £379,053 for the management fee has now been settled. The portfolio is valued under IFRS at bid price.
Total Assets stand at £4.9 million and Investments stand at £4.4 million. This quarter's NAV represents a decrease of 1.97% from the previous valuation of 14.71 pence per share, which included un-invested cash of £526,503. On this basis, no additional management fee is due to Shellbay Investments Limited.
Our holding in the Magna Biopharma Income Fund continues to perform well, the value having risen by 12% to £2.6 million in the nine months since inception.
The Directors' intend to make a further announcement about the distribution of Magna Biopharma Income Fund shares at the end of the month which marks the conclusion of the lock-in period."
|
|
Unaudited to 30 September 2014 £ |
Fixed Assets |
|
|
|
Investments
|
4,408,633
|
Current Assets |
|
|
|
Debtors: amounts owing |
24,477 |
|
Un-invested cash
|
490,797
|
Current Liabilities |
|
|
|
Creditors: amounts due
|
(39,027)
|
|
|
4,884,880
|
Capital and Reserves |
|
|
|
Share Capital |
34 |
|
Share Premium |
2,759,551 |
|
Current year's earnings |
(96,546) |
|
Retained earnings
|
2,221,841 |
|
|
4,884,880
|
|
||
Shares in Issue
|
|
33,864,836 |
Asset Value per share |
|
14.42 pence |
|
||
|
||
|
||
|
--- ENDS ---
Portfolio Details
Investments as at 30 September 2014 |
Value |
% of Total Portfolio |
|
Magna Biopharma Income Fund |
£2,613,899 |
59.29% |
|
Plethora Solutions Holdings |
£600,625 |
13.62% |
|
Summit Corporation |
£586,499 |
13.30% |
|
Other quoted holdings |
£209,110 |
4.74% |
|
Other unquoted holdings |
£398,500 |
9.04% |
|
Total |
£4,408,633 |
100.00% |
|
For further information, please contact:
Port Erin Biopharma Investments Limited |
Beaumont Cornish Limited |
Peterhouse Capital Limited |
The Company |
Nomad |
Broker |
Denham Eke +44 162 463 9396 |
Roland Cornish +44 207 628 3396 |
Guy Miller +44 207 469 0930 |